Multiple in vitro (human LX-2; normal and activated rat HSCs) and in vivo (transgenic and CCl4-treated mice) studies supporting the roles of EP300 in liver fibrosis are reported in literatureStudies supporting the roles of EP300 in non-liver fibrosis, lipid metabolism/NAFLD, and inflammation. Here, EP300 is linked to metabolic dysfunction-associated steatotic liver disease.